
Comprehensive genomic analysis of early and late-onset hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the major histologic type of primary liver cancer, accounting for approximately 75% of liver cancer cases.1 Despite many advancements in its treatment, the prognosis and drug response of HCC patients are dismal. Therefore, there is an unmet clinical need to explore genomic aberrations underlying early- and late-onset HCC, which might facilitate drug discovery and provide personalized biomarker-driven treatment options for these patients. This study aimed to identify biomarkers associated with early-onset (EO) and late-onset (LO) HCC with comprehensive genomic profiling.